# Neuropathic Pain Market

> Neuropathic Pain Market Research Report By Type of Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, Chemotherapy-Induced Peripheral Neuropathy), By Treatment Type (Medications, Physical Therapy, Surgical Procedures, Electrical Stimulation), By Route of Administration (Oral, Topical, Injectable), By End User (Hospitals, Clinics, Home Care) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 9.71%
- **2025:** USD 8.48 Billion
- **2035:** USD 21.32 Billion
- **Key Players:** Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries, Grünenthal GmbH, Vertex Pharmaceuticals, Sanofi S.A., Sun Pharmaceutical Industries, Endo, Inc.

**Report ID:** MRFR/HC/0881-CR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 25, 2026

**URL:** https://www.marketresearchfuture.com/reports/neuropathic-pain-market-1390

---

## Market Summary

The Global Neuropathic Pain Market size was valued at USD 7.8 Billion in 2024, and the market is projected to grow from USD 8.355 Billion in 2025 to USD 16.62 Billion by 2035, registering a CAGR of 7.12% during the forecast period 2025–2035. North America led the market in 2024 with over 31.41% share, generating around USD 2.45 Billion in revenue.
 
Rising prevalence of chronic neurological disorders and increasing demand for effective pain management therapies are major growth drivers. Advancements in pharmacological and non-pharmacological treatments, along with improved diagnosis, are enhancing patient outcomes and expanding the global neuropathic pain treatment market.
 
According to the World Health Organization (WHO), over 1 billion people globally suffer from neurological disorders, while the Institute for Health Metrics and Evaluation (IHME) reports these conditions contribute to over 10% of global DALYs, highlighting strong demand for neuropathic pain treatment solutions.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising global diabetes prevalence | 2.4 | Global; acute in APAC, MEA | Long-term (≥4 yr) | [2] |
| Non-opioid reimbursement reform | 1.9 | North America, EU5 | Short-term (≤2 yr) | [1] |
| Expanding cancer survivorship | 1.5 | North America, Europe, Japan | Medium-term (2–4 yr) | [9] |
| Novel mechanism approvals (NaV blockers) | 1.4 | Global | Medium-term (2–4 yr) | [3] |
| Ageing population and herpes zoster burden | 1.1 | Europe, Japan, China | Long-term (≥4 yr) | [10] |
| Specialty pain-clinic infrastructure buildout | 0.8 | APAC, South America | Medium-term (2–4 yr) | [8] |
| Telehealth-enabled chronic pain follow-up | 0.6 | North America, Nordics | Short-term (≤2 yr) | [11] |

### Diabetes Epidemiology Is the Structural Engine

Here, diabetes is the demand curve rather than a background variable. Adult prevalence is estimated to be 11.1% worldwide in the International Diabetes Federation's 2025 Atlas, with 589 million cases expected to rise to 853 million by 2050 [[2]](https://diabetesatlas.org). According to peer-reviewed cohort studies, 20–26% of that population has painful diabetic neuropathy, yet treatment rates in high-income systems are still close to 60%. This means that as screening improves, a sizable untreated pool becomes profitable. Every type 2 patient at diagnosis should now undergo annual monofilament and vibration testing, according to the American Diabetes Association's 2025 Standards of Care [[12]](https://diabetesjournals.org). This screening requirement mechanically expands the diagnosed base annually.

### Payer Policy Rewrote the Non-Opioid Economics

For twenty years, the chemicals that were prescribed were determined more by reimbursement than by research. This was altered on January 1, 2025, when CMS instituted separate outpatient payment for qualifying non-opioid analgesics under Section 4135 of the Consolidated Appropriations Act. The provision was authorized through 2027 and covered medications and devices that met FDA-approved pain-indication criteria [[1]](https://cms.gov). Hospitals now bill individually for non-opioid expenses that were previously covered by bundled payments. Early claims analysis indicates that throughout the first two quarters, non-opioid analgesic line items increased by 14–18% in all participating outpatient departments.

### Mechanism Innovation Restores Pricing Power

Approval of the first new oral analgesic class in more than twenty years reset expectations. Suzetrigine, a selective NaV1.8 inhibitor cleared by FDA in January 2025 for moderate-to-severe acute pain, carries an active Phase III programme in painful diabetic peripheral neuropathy with topline data anticipated in 2026 [[3]](https://fda.gov). A successful readout would open a chronic indication priced well above the USD 0.30–0.90 per-day economics of generic gabapentinoids. Investors have already repriced the sector accordingly: neuropathic pain-focused biotechs raised roughly USD 2.7 billion across venture and follow-on rounds during 2024–2025 [[13]](https://bioworld.com).

### Cancer Survivorship Creates a Durable Secondary Pool

Survival gains produce their own morbidity. Roughly 68% of patients report chemotherapy-induced peripheral neuropathy within one month of taxane or platinum exposure, and 30% remain symptomatic beyond six months [[9]](https://journals.lww.com). With global cancer survivors expected to exceed 26 million by 2030, oncology supportive care becomes a standing procurement category rather than an episodic one. NCCN's 2024 supportive-care update elevated duloxetine to a category 1 recommendation for established CIPN [[14]](https://nccn.org), giving payers a defensible protocol to fund.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Genericisation of anticonvulsants and SNRIs | 1.8 | Global | Short-term (≤2 yr) | [15] |
| Modest effect sizes and high placebo response | 1.3 | Global | Long-term (≥4 yr) | [16] |
| Regulatory scrutiny of gabapentinoid misuse | 0.9 | UK, US, Nordics | Medium-term (2–4 yr) | [17] |
| Diagnostic underdetection in primary care | 0.7 | APAC, MEA, South America | Long-term (≥4 yr) | [8] |
| Payer step-therapy and prior-authorisation friction | 0.6 | North America, Germany | Medium-term (2–4 yr) | [18] |

### Price Erosion Outruns Volume in Mature Molecules

Value growth is more difficult than volume increase. By 2025, generics accounted for over 87% of anticonvulsant prescription volume in the US and contributed less than 35% of class revenue [[15]](https://iqvia.com). Pregabalin lost U.S. exclusivity in 2019, but duloxetine did so much earlier. The amount that epidemiological expansion translates into revenue is capped by that wedge. In response, manufacturers offer fixed-dose combos and extended-release reformulations; nevertheless, payers are increasingly refusing premium placement in the absence of head-to-head functional superiority data.

### Clinical Efficacy Ceilings Constrain Adoption

The number-needed-to-treat statistics are still unyielding. NNT for 50% pain reduction is 6.4 for [pregabalin](https://www.marketresearchfuture.com/reports/pregabalin-market-41097) and 7.2 for gabapentin, according to the NeuPSIG systematic review [[16]](https://thelancet.com). Placebo response rates in registration studies often surpass 30%. As a result, doctors cycle patients through several medications, and about 40% stop using them within a year. A number of nerve-growth-factor antibody programs halted due to quickly progressing osteoarthritis signals, eliminating an expected growth vector, which exacerbates the issue.

### Regulatory Tightening Around Gabapentinoids

Safety oversight has narrowed prescribing latitude. The United Kingdom reclassified pregabalin and gabapentin as Class C controlled substances in 2019, and MHRA drug-safety updates through 2024 reinforced respiratory-depression warnings when combined with [opioids](https://www.marketresearchfuture.com/reports/opioids-market-7626) [[17]](https://gov.uk). Similar signals appear in FDA labelling and in several EU national formularies. The practical result is a documentation burden that slows initiation, particularly in primary care where most first prescriptions originate.

## Opportunities

## Neuropathic Pain Market Opportunities

### Outcome-Linked Contracting

Payers want function, not just pain scores. Contracts tying rebate levels to validated measures — six-minute walk distance, PROMIS Physical Function, sleep-interference indices — let differentiated agents defend premium pricing where head-to-head analgesia data is ambiguous. Early pilots in German sickness funds and U.S. integrated delivery networks suggest 8–12% net-price protection for products that can supply longitudinal functional evidence [[18]](https://g-ba.de).

### Topical and Localised Delivery

Route matters as much as molecule. High-concentration capsaicin patches and lidocaine systems deliver relief without cognitive load, an advantage in patients over 70 where polypharmacy is standard. This is the fastest-compounding route in the Neuropathic Pain Market and the clearest near-term white space for mid-cap specialty firms lacking discovery-stage pipelines.

### Emerging-Market Access Expansion

China's National Reimbursement Drug List negotiations have repeatedly traded steep price concessions for volume, and India's Ayushman Bharat scheme now covers over 550 million beneficiaries with expanding chronic-disease provisions [[7]](https://nhsa.gov.cn)[[8]](https://icmr.gov.in). Brazil's ANVISA has accelerated generic approvals for pregabalin analogues. Firms willing to accept 55–70% price discounts can capture unit volumes that dwarf Western cohorts.

### Real-World Evidence as a Revenue Line

Longitudinal pain registries are becoming saleable assets. De-identified adherence, titration, and outcome datasets from digital therapeutics platforms now command licensing fees from pharmaceutical sponsors seeking synthetic control arms and label-expansion evidence. Several digital pain platforms report data-licensing revenue exceeding 20% of total income [[11]](https://oecd.org).

### Precision Phenotyping and Stratified Trials

Sensory-profile stratification — irritable versus deafferented nociceptor phenotypes — improved responder identification in several EU-funded consortia. Sponsors adopting quantitative sensory testing at screening report trial sample-size reductions near 30%, cutting development cost materially [[19]](https://journals.lww.com).

## Future Outlook

## Neuropathic Pain Market Future Outlook

### Digital Phenotyping and Algorithmic Titration

Wearable-derived sleep fragmentation and gait data now correlate meaningfully with neuropathic symptom severity, and several regulator-cleared software tools use those inputs to recommend dose adjustments between clinic visits. The WHO estimates that digital health interventions could improve chronic-disease adherence by 15–25% in resource-constrained systems [[22]](https://who.int). Expect titration algorithms to become a standard companion offering rather than a differentiator by 2030.

### Value-Based Contracting Becomes Default

Risk-sharing arrangements in analgesia lagged oncology by roughly a decade. That gap is closing as electronic patient-reported outcome capture matures, and by the early 2030s a majority of branded launches in developed markets will likely carry some outcomes-linked rebate component. The Neuropathic Pain Market rewards this shift because functional gain is measurable and defensible.

### Mechanism Diversification Beyond Ion Channels

Sodium-channel selectivity dominates current pipelines, but angiotensin type-2 receptor antagonists, TRPV1 modulators, and gene-therapy approaches targeting dorsal root ganglia are progressing. NIH's HEAL Initiative has committed more than USD 4 billion since 2018 across pain research, with a substantial neuropathic allocation [[23]](https://heal.nih.gov). Diversification reduces the sector's exposure to any single mechanistic failure.

### Manufacturing Localisation and Supply Resilience

API concentration remains a quiet risk. A majority of gabapentinoid intermediates originate from a small number of Chinese and Indian facilities, and the 2024 EU Critical Medicines Act proposals explicitly targeted analgesic supply security [[24]](https://ec.europa.eu). Reshoring incentives in the U.S., EU, and India will raise unit costs modestly while reducing shortage frequency — a trade most procurement officers now accept.

## Segment Insights

## Neuropathic Pain Market Segmentation

### By Drug Class

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Anticonvulsants | 31.1% share | First-line guideline status; broad generic availability |
| Tricyclic Antidepressants | USD 1.48 Billion | Low cost; entrenched primary-care prescribing |
| SNRIs | USD 1.34 Billion | Category 1 recommendation in CIPN |
| Opioid Analgesics | 14.2% share | Refractory and palliative use only |
| Topical Agents | 10.37% CAGR | Cognitive-sparing profile in elderly patients |
| Local Anesthetics & Others | 8.9% share | Interventional and adjunct protocols |

Anticonvulsants remain the volume backbone of the Neuropathic Pain Market despite severe price compression, because guidelines from NeuPSIG, NICE, and the ADA all position gabapentinoids as first-line. The class's revenue share understates its prescription share by a wide margin. Topical agents tell the opposite story — modest volume, superior economics. An 8% capsaicin patch administered quarterly generates annualised revenue several multiples above daily generic oral therapy, and its localised action avoids the sedation that drives elderly discontinuation.

### By Indication

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Diabetic Peripheral Neuropathy | 30.0% share | 589 million diabetic adults globally |
| Postherpetic Neuralgia | USD 1.37 Billion | Ageing populations in Japan and EU5 |
| Chemotherapy-Induced Peripheral Neuropathy | 11.71% CAGR | Rising survivorship; NCCN protocol support |
| Trigeminal Neuralgia | 10.8% share | Carbamazepine standard of care |
| Post-Surgical & Trauma Nerve Injury | USD 0.97 Billion | Perioperative prevention protocols |
| Central Neuropathic Pain | 10.6% share | Multiple sclerosis and spinal cord injury cohorts |
| HIV-Associated & Others | 7.5% share | Antiretroviral-era survivorship |

Diabetic peripheral neuropathy anchors the Neuropathic Pain Market and will continue to, given that incidence tracks a metabolic epidemic no health system has reversed. Chemotherapy-induced peripheral neuropathy is the more interesting growth story: it is acute-onset, protocol-associated, and therefore highly predictable for procurement planning. Oncology pharmacies can forecast demand from regimen mix alone, which makes the segment unusually attractive for supply contracting.

### By Route of Administration

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Oral | 57.7% share | Convenience and generic cost structure |
| Topical / Transdermal | 12.23% CAGR | Localised efficacy without systemic burden |
| Injectable / Parenteral | USD 1.43 Billion | Interventional blocks and refractory cases |
| Others | 7.0% share | Intrathecal and implantable delivery |

Oral dominance persists because it is cheap and familiar, not because it is optimal. Topical and transdermal delivery is the structural gainer across the Neuropathic Pain Market, particularly for localised presentations such as postherpetic neuralgia where the painful territory is well demarcated.

### By Distribution Channel

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 39.2% share | Initiation and titration under specialist supervision |
| Retail Pharmacies | USD 3.15 Billion | Chronic refill volume |
| Online Pharmacies | 12.11% CAGR | Telehealth-linked chronic prescribing |
| Others | 8.3% share | Long-term care and mail-order institutional supply |

Hospital pharmacies capture initiation; retail captures maintenance. Online channels are the fastest-growing route in the Neuropathic Pain Market, benefiting from telehealth follow-up rules that several regulators made permanent after 2023.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.4% share | Non-opioid reimbursement, specialty clinics, novel mechanism launches |
| Europe | USD 2.34 Billion | HTA functional endpoints, topical adoption, ageing cohorts |
| Asia-Pacific | 12.59% CAGR (2026–2035) | NRDL listings, diabetes screening, domestic generics |
| South America | USD 0.54 Billion | Public formulary expansion, local manufacturing |
| Middle East & Africa | 4.8% share | Diabetes centres of excellence, private insurance growth |
| Total | USD 8.48 Billion | — |

Revenue distribution across the Neuropathic Pain Market reflects diagnostic infrastructure more than disease burden. Regions with organised pain-medicine specialties convert prevalence into prescriptions; regions without them do not.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 86.1% of region | NOPAIN Act separate payment; commercial payer breadth |
| Canada | USD 0.31 Billion | Provincial formulary harmonisation |
| Mexico | 9.42% CAGR | IMSS diabetes screening expansion |

Reimbursement architecture explains the region's dominance in the Neuropathic Pain Market. The United States funds roughly 5,400 accredited pain-medicine physicians and a dense network of ambulatory surgical centres now able to bill non-opioid analgesics outside the bundle [[1]](https://cms.gov). Canada's pan-Canadian Pharmaceutical Alliance negotiates jointly for provincial plans, compressing prices but guaranteeing listing breadth. Mexico's IMSS expanded diabetic foot and neuropathy screening across 1,200 primary units in 2024, converting undiagnosed prevalence into treated demand.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.8% of region | G-BA benefit assessment favouring functional endpoints |
| UK | USD 0.36 Billion | NICE NG193 chronic pain pathway |
| France | 15.1% of region | HAS reimbursement for capsaicin patches |
| Italy | USD 0.24 Billion | AIFA regional tender consolidation |
| Spain | 9.7% of region | Andalusian and Catalan diabetes registries |
| Nordic Countries | 8.11% CAGR | Digital pain-management pilots |
| Russia | USD 0.13 Billion | Domestic generic substitution |
| Rest of Europe | 7.4% of region | CEE access programmes |

Health technology assessment shapes European outcomes more than clinical guidelines do. Germany's G-BA has repeatedly downgraded added-benefit ratings where sponsors submitted pain-score data without function or quality-of-life measures, and that precedent now drives trial design across the EU5 [[18]](https://g-ba.de). The United Kingdom's NICE guideline NG193 controversially discouraged routine gabapentinoid initiation for primary chronic pain while preserving it for confirmed neuropathic aetiologies, sharpening diagnostic rigour. Nordic systems, with unified electronic records, run the continent's most credible real-world evidence programmes.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 38.6% of region | NRDL listings and 148 million diabetic adults |
| India | 14.12% CAGR | Ayushman Bharat chronic-disease coverage |
| Japan | USD 0.42 Billion | Ageing cohort and postherpetic neuralgia burden |
| South Korea | 8.2% of region | HIRA reimbursement for topical agents |
| ASEAN | USD 0.17 Billion | Rising private insurance penetration |
| Rest of Asia-Pacific | 5.9% of region | Urban pain-clinic buildout |

Volume, not price, defines the opportunity here. China hosts the world's largest diabetic population and has listed multiple neuropathic analgesics through NRDL negotiation rounds at discounts of 50–70%, trading margin for national access [[7]](https://nhsa.gov.cn). India's diabetic base exceeds 101 million adults, yet treated penetration for painful neuropathy remains under 25%, leaving substantial headroom [[8]](https://icmr.gov.in). Japan's demography drives a different mix: herpes zoster incidence rises sharply past age 65, and Japan's shingles vaccination programme has not yet blunted the prevalent postherpetic neuralgia pool.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% of region | SUS formulary inclusion; ANVISA generic approvals |
| Argentina | USD 0.09 Billion | PAMI coverage for elderly beneficiaries |
| Rest of South America | 10.24% CAGR | Chile and Colombia private-payer growth |

Public procurement dictates the pace across the continent. Brazil's Sistema Único de Saúde purchases at tender, and inclusion in the RENAME essential medicines list effectively determines whether a molecule achieves scale [[20]](https://gov.br/saude). Local manufacturing incentives under Brazil's PDP partnership framework have pulled several multinationals into technology-transfer agreements. Argentina's macroeconomic volatility complicates pricing, though PAMI's elderly coverage sustains a reliable postherpetic neuralgia volume base.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 31.7% of region | Vision 2030 diabetes centres of excellence |
| UAE | USD 0.07 Billion | Mandatory health insurance in Dubai and Abu Dhabi |
| South Africa | 17.4% of region | HIV-associated neuropathy burden |
| Egypt | 10.96% CAGR | Universal Health Insurance rollout |
| Rest of MEA | 12.8% of region | Private-sector clinic expansion |

Gulf states punch above their population weight in the Neuropathic Pain Market because prevalence and purchasing power coincide. Saudi Arabia records adult diabetes prevalence near 18%, among the highest globally, and the Health Sector Transformation Program has funded dedicated endocrine and pain facilities across the Kingdom [[21]](https://vision2030.gov.sa). South Africa's picture differs: antiretroviral-era survivorship left a large cohort with distal sensory polyneuropathy, sustaining demand for low-cost oral agents. Egypt's phased universal insurance rollout, targeting national coverage by 2032, represents the region's largest access expansion.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits in the medium band. Market Research Future estimates a Herfindahl-Hirschman Index of roughly 780–860 for the global Neuropathic Pain Market, with the top five suppliers holding an estimated 38–44% of value. Genericisation fragments the anticonvulsant and antidepressant pools while branded topicals and emerging mechanism-based agents concentrate value at the premium end. The result is a barbell: high-volume commodity players competing on cost, and a smaller cohort of innovators competing on differentiated mechanism and outcome evidence.

| Company | Est. Revenue Share Range | Key Offerings for Neuropathic Pain Market | Strategic Positioning |
| --- | --- | --- | --- |
| Pfizer Inc. | ~9–12% | Pregabalin franchise; gabapentin portfolio | Legacy brand equity; defending against generics |
| Viatris Inc. | ~7–10% | Generic pregabalin, duloxetine, gabapentin | Scale generics; global tender specialist |
| Teva Pharmaceutical Industries | ~6–9% | Broad generic analgesic portfolio | Cost leadership; deep formulary penetration |
| Grünenthal GmbH | ~5–8% | High-concentration capsaicin patch; lidocaine plaster | Topical specialist; EU pain-clinic channel |
| Eli Lilly and Company | ~4–7% | Duloxetine franchise | SNRI heritage; oncology supportive-care overlap |
| Vertex Pharmaceuticals | ~3–6% | NaV1.8 selective inhibitor programme | Mechanism innovator; premium-price pathway |
| Sanofi S.A. | ~3–5% | Analgesic and adjuvant portfolio | Broad primary-care reach |
| Sun Pharmaceutical Industries | ~3–5% | Generic and branded-generic neuropathic agents | Emerging-market volume leader |
| Endo, Inc. | ~2–4% | Lidocaine transdermal systems | Topical niche; U.S. specialty channel |
| Bausch Health Companies | ~2–4% | Neuropathic and adjunct analgesics | Diversified specialty pharma |
| Daiichi Sankyo Company | ~2–4% | Mirogabalin (Asia-focused) | Japan and APAC differentiation |
| Novartis AG | ~1–3% | Carbamazepine and adjacent CNS agents | Trigeminal neuralgia legacy franchise |

## Recent News & Developments

## Recent News & Developments

- U.S. Food and Drug Administration (January 2025): Approved suzetrigine, the first NaV1.8-selective oral analgesic, establishing a regulatory precedent for peripherally acting non-opioid mechanisms and validating a chronic-indication pathway now in Phase III [[3]](https://fda.gov)
- Centres for Medicare & Medicaid Services (January 2025): Activated separate outpatient payment for qualifying non-opioid analgesics, removing a longstanding reimbursement disincentive in hospital outpatient departments and ambulatory surgical centres [[1]](https://cms.gov)
- Grünenthal (September 2024): Expanded European commercial infrastructure for its high-concentration capsaicin patch, adding specialist territory coverage across CEE markets [[5]](https://ema.europa.eu)
- National Healthcare Security Administration, China (December 2024): Concluded the annual National Reimbursement Drug List negotiation round, adding analgesic and neurology products at negotiated discounts and materially widening patient access [[7]](https://nhsa.gov.cn)
- Eli Lilly (June 2024): Published extended follow-up data supporting duloxetine's durability in chemotherapy-induced peripheral neuropathy, reinforcing its category 1 guideline position [[14]](https://nccn.org)
- Viatris (March 2024): Completed portfolio rationalisation of legacy analgesic assets, redirecting capital toward complex generics and injectable capacity [[15]](https://iqvia.com)
- European Commission (April 2024): Advanced the Critical Medicines Act framework identifying analgesics among supply-vulnerable categories, prompting reshoring commitments from three API producers [[24]](https://ec.europa.eu)
- National Institutes of Health, HEAL Initiative (October 2023): Awarded a new tranche of translational pain research grants, with dedicated funding streams for non-addictive neuropathic therapeutics and biomarker discovery [[23]](https://heal.nih.gov)

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global prescription and specialty therapeutics indicated for neuropathic pain, segmented by drug class, indication, route of administration, distribution channel, and geography |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 9.71% (2026–2035) |
| Market Size Checkpoints | USD 8.48 Billion (2025); USD 9.25 Billion (2026); USD 14.71 Billion (2031); USD 21.32 Billion (2035) |
| Fastest Growing Segments | Chemotherapy-induced peripheral neuropathy (indication); topical/transdermal (route); online pharmacies (channel); Asia-Pacific (geography) |
| Companies Profiled | Pfizer, Viatris, Teva, Grünenthal, Eli Lilly, Vertex, Sanofi, Sun Pharmaceutical, Endo, Bausch Health, Daiichi Sankyo, Novartis |
| Valuation Currency | USD Billion, constant 2025 exchange rates |

## Frequently Asked Questions

**Q: How should procurement teams structure tenders for the Neuropathic Pain Market when generics dominate volume?**
A: Split tenders by therapeutic role rather than by molecule. Award commodity orals on price alone, but evaluate topicals and novel mechanisms on total cost of care, including fall and hospitalisation avoidance [15].

**Q: What licensing structures do mid-cap firms use to enter emerging geographies?**
A: Regional co-promotion with a local manufacturer typically outperforms direct entry, since domestic partners already hold tender registrations. Royalty bands of 8–15% on net sales are standard [8].

**Q: Which clinical endpoints most influence payer decisions in the Neuropathic Pain Market today?**
A: Functional measures now outrank pain-intensity deltas at most European HTA bodies. Sponsors submitting only numeric rating scale data risk downgraded benefit ratings [18].

**Q: How do interventional devices compete with pharmacological options?**
A: Spinal cord stimulation and dorsal root ganglion stimulation target refractory patients after drug failure, so overlap is limited. Device growth expands rather than cannibalises the pharmaceutical pool [23].

**Q: What supply-chain risks should buyers monitor?**
A: Active pharmaceutical ingredient concentration in a handful of Asian facilities creates single-point failure exposure. Dual-sourcing clauses and 90-day safety stock are increasingly written into hospital contracts [24].

**Q: Are there meaningful reimbursement differences for diabetic neuropathy therapy across the Neuropathic Pain Market?**
A: Coverage varies sharply. Several EU systems require documented failure of two oral agents before funding topicals, while U.S. commercial plans increasingly waive step therapy post-2025 [1].

**Q: What does the pipeline suggest about pricing five years out?**
A: Mechanism-differentiated launches should sustain premium tiers, but only where functional superiority is demonstrated. Undifferentiated entrants will face generic-equivalent reference pricing within 18 months of launch [13].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neuropathic-pain-market-1390*